A study found that a single dose of trastuzumab drug can significantly reduce HER2-positive breast cancer tumors. When trastuzumab is taken with pertuzumab or other HER2-targetting treatments, about 60 percent of the participants will have a complete response.
A study found that a single dose of trastuzumab drug can significantly reduce HER2-positive breast cancer tumors. When trastuzumab is taken with pertuzumab or other HER2-targetting treatments, about 60 percent of the participants will have a complete response.
Share this Article
Recommended